PLI Grants vs MAT: How Section 115JB Interacts with PLI Income

A Tier-2 biosimilars formulator running its India commercial book for FY 2026-27 receives a Production Linked Incentive quarterly disbursement of the order of Rs 62 crore from the Department of Pharmaceuticals — the Year 4 grant under the Rs 15,000 crore PLI Pharmaceuticals scheme, computed at 10 percent of the Category 1 incremental sales for the eligible year. The grant is recognised as book income under Ind AS 20 (Accounting for Government Grants) and flows into the statement of profit and loss for the year. The company’s audited Ind AS book profit sits of the order of Rs 1,240 crore. Section 115JB of the Income Tax Act 1961 applies its 15 percent Minimum Alternate Tax on adjusted book profit computed under Explanation 1 to the section. The PLI grant does not appear in either the Explanation 1 add-back schedule or the Explanation 1 reduction schedule — it flows through untouched into the MAT base. The effective MAT on the PLI grant sits at 15 percent (plus applicable surcharge and health-and-education cess). At the same time, the finance team must evaluate the Section 115BAA 22 percent concessional-rate election — an irrevocable option that would surrender the Section 35(2AB) in-house R&D weighted deduction and Chapter VI-A deductions other than Section 80JJAA, and would forfeit any unutilised MAT credit carried forward under Section 115JAA. This is PLI grants MAT Section 115JB pharma interaction at the year-end tax-provisioning surface — and the discipline that separates a defensible tax memo from a Form 29B rework is a three-register integration between the PLI grant register, the Section 115JB book-profit workbook, and the Section 115JAA MAT credit ledger.

Quick reference

The reconciliation in one paragraph

A Chapter 30 pharma formulator receiving a PLI Category 1 quarterly disbursement records the grant in the statement of profit and loss under Ind AS 20 as either other income or as a deduction from cost of goods sold — either presentation increases the book profit for the year. Section 115JB of the Income Tax Act 1961 applies the 15 percent Minimum Alternate Tax on adjusted book profit, computed by starting from the Ind AS profit for the year and applying the Explanation 1 add-backs (income tax, transfer to reserves, unascertained provisions, depreciation, deferred tax) and reductions (amount withdrawn from reserves, brought-forward loss or unabsorbed depreciation whichever is less). The PLI grant is not among the specified adjustments — it flows through as book income. Where MAT (15 percent of adjusted book profit) exceeds the normal-regime tax (30 percent of total income after Section 35(2AB) weighted deduction and Chapter VI-A deductions), MAT is binding for the year, and the excess is a Section 115JAA MAT credit carried forward for 15 assessment years, recognised as an Ind AS 12 deferred tax asset subject to the recoverability probability assessment. The parallel Section 115BAA scenario — 22 percent concessional rate, no Section 35(2AB), no MAT, MAT credit lapse — is evaluated as a year-on-year scenario model and documented in the tax memo before the irrevocable election is made (if ever).

What the scenario looks like in India

The Rs 15,000 crore PLI Pharmaceuticals scheme, notified by the Department of Pharmaceuticals on 3 March 2021, covers FY 2020-21 through FY 2028-29 and distributes incentive across three product categories at differentiated rates. Category 1 — biopharmaceuticals including biosimilars, complex generic drugs, patented drugs or drugs nearing patent expiry, cell-based or gene-therapy products, orphan drugs, special empty capsules, complex excipients, and phyto-pharmaceuticals — carries the highest incentive rate at 10 percent of incremental sales for Years 1 to 4, tapering to 8 percent in Year 5 and 6 percent in Year 6. Category 2 (active pharmaceutical ingredients, key starting materials, drug intermediates) and Category 3 (repurposed drugs, in-vitro diagnostic devices, other drugs) carry lower rates that step down through the scheme window. The PLI Pharma Categories 1, 2 and 3 differential treatment reference walks the eligibility taxonomy and the sub-category application mechanics; the PLI Pharmaceuticals Rs 15,000 crore eligibility and incremental-sales reconciliation reference walks the underlying eligibility and incremental-sales computation. The tax overlay this article addresses sits downstream of both.

Illustrative Tier-2 pharma formulators most likely to be Category 1 PLI recipients — because their product portfolios skew biosimilars, complex generics and rare-disease drugs — include Biocon Biologics, Piramal Pharma, Ipca Laboratories, Ajanta Pharma, Natco Pharma, Laurus Labs, Granules India, Strides Pharma Science, and JB Chemicals & Pharmaceuticals. Tier-1 integrated formulators with Category 1 sub-portfolios include Sun Pharmaceutical Industries (specialty and complex generics), Dr Reddy’s Laboratories (biosimilars and complex generics), Cipla (biosimilars and inhalation devices), Aurobindo Pharma (complex generics and biosimilars), Lupin (biosimilars and complex generics), Zydus Lifesciences (biosimilars and vaccine complex generics), and Glenmark Pharmaceuticals (complex generics and biosimilars). The reference persona for this article is a Tier-2 biosimilars-heavy formulator with an FY 2026-27 audited Ind AS book profit of the order of Rs 1,240 crore, of which the order of Rs 62 crore represents PLI Category 1 quarterly disbursements recognised as book income under Ind AS 20 for the year.

The regulatory overlay — Section 115JB, Ind AS 20, Section 115BAA and Section 115JAA

Section 115JB of the Income Tax Act 1961 provides that where the income tax payable on the total income of a company computed under the normal provisions is less than 15 percent of its book profit, the book profit is deemed to be the total income and tax is payable at 15 percent (plus applicable surcharge and health-and-education cess). Book profit is the net profit shown in the statement of profit and loss for the relevant previous year prepared under Schedule III of the Companies Act 2013 — or under the applicable Ind AS framework — as increased by the items in Explanation 1 clauses (a) to (k) and as reduced by the items in clauses (i) to (viii). The Explanation 1 add-back items include income tax paid or payable, amounts transferred to reserves, provisions for unascertained liabilities, depreciation, deferred tax, and specified other items. The Explanation 1 reduction items include amounts withdrawn from reserves credited to the profit and loss, brought-forward loss or unabsorbed depreciation whichever is less, profits of a sick industrial company, and specified other items. PLI grant income recognised under Ind AS 20 is NOT among the specified add-back or reduction items in Explanation 1. It flows through the book-profit computation unchanged.

Ind AS 20 (Accounting for Government Grants and Disclosure of Government Assistance) provides that government grants shall be recognised in profit or loss on a systematic basis over the periods in which the entity recognises as expenses the related costs for which the grants are intended to compensate — the grant-related-to-income treatment. A PLI grant tied to incremental sales — where the grant compensates the entity for the incremental commercial activity and production cost of the incremental output — is a grant related to income and is recognised in the statement of profit and loss as the incremental sales that entitle the entity to the grant are recognised. The grant is presented either as other income or as a deduction from the related expense, at the entity’s accounting policy choice; in either presentation the grant increases the book profit for the period.

Section 115BAA of the Income Tax Act 1961 provides a concessional 22 percent corporate tax rate for a domestic company that irrevocably elects into the regime. The effective rate including 10 percent surcharge and 4 percent health-and-education cess sits at approximately 25.17 percent. The electing company must compute total income without claiming Section 10AA (SEZ profits), Section 32(1)(iia) (additional depreciation), Section 32AD, Section 33AB, Section 33ABA, Section 35(1)(ii)/(iia)/(iii)/35(2AA)/35(2AB) (scientific research including in-house R&D weighted deduction), Section 35AD, Section 35CCC, Section 35CCD, and Chapter VI-A except Section 80JJAA and Section 80M. The company is NOT subject to MAT under Section 115JB and is not entitled to carry forward or utilise MAT credit under Section 115JAA — any unutilised MAT credit lapses on the election. The Section 35(2AB) weighted deduction pharma R&D reconciliation guide walks the DSIR-approved R&D deduction mechanic that Section 115BAA surrenders — and is the single most consequential surrendered item for an R&D-heavy pharma company.

Section 115JAA provides that where a company pays MAT under Section 115JB in excess of the tax it would have paid under the normal provisions, the excess is a tax credit that can be carried forward for fifteen assessment years immediately succeeding the assessment year in which the credit arose. In a subsequent year, if the tax payable under the normal provisions exceeds the MAT applicable that year, the company can set off the carried-forward credit up to the amount of the excess. Under Ind AS 12 the MAT credit is an unused tax credit; a deferred tax asset is recognised for the credit to the extent that it is probable sufficient future taxable profit at the normal-regime rate will be available within the 15-year window to utilise the credit.

A worked example — an illustrative Tier-2 biosimilars formulator at FY 2026-27 close

Illustrative — the following figures represent the operating pattern of a Tier-2 pharma formulator receiving PLI Category 1 disbursements at Year 4 of the scheme window. Public disclosures do not reveal per-company PLI grant amounts, Section 115JB adjusted book profit or Section 115JAA MAT credit balances in the granularity below; cross-verify against your own audited financial statements, tax audit report Form 3CB-3CD, and MAT report Form 29B before action.

The company closes FY 2026-27 with the following Ind AS profit-and-loss and tax computation, in Rs crore:

The parallel normal-regime tax computation:

Comparing the two: MAT under Section 115JB is Rs 193 crore; normal-regime tax is Rs 155 crore. MAT exceeds normal tax by Rs 38 crore, so MAT is binding for the year. The tax payable for FY 2026-27 is Rs 193 crore. The excess of Rs 38 crore is a Section 115JAA MAT credit carried forward for 15 assessment years — recoverable in a future year when normal-regime tax exceeds MAT for that future year. Under Ind AS 12 the finance team recognises a deferred tax asset of Rs 38 crore for the MAT credit, subject to the recoverability probability assessment documented in the tax memo. The Ind AS 12 note in the audited financial statements discloses the DTA carrying value and the underlying assumptions.

The effective MAT on the PLI grant slice specifically: PLI grant of Rs 62 crore is fully in the Rs 1,240 crore book-profit base and flows through to the Rs 1,285 crore adjusted book profit unchanged. At the 15 percent MAT rate (plus surcharge and cess), the effective MAT on the PLI grant sits of the order of Rs 9.3 crore before surcharge and cess, or approximately Rs 10.8 crore including surcharge and cess.

The parallel Section 115BAA scenario, evaluated as a decision memo:

Section 115BAA tax of Rs 348.6 crore vastly exceeds the base-case MAT of Rs 193 crore — because the surrendered Section 35(2AB) weighted R&D deduction is highly material for the biosimilars-heavy company, and the accumulated MAT credit (Rs 38 crore this year plus any carry-forward from prior years) would lapse. The decision for the company at this profit and R&D profile is to stay in the normal regime, generate MAT credit under Section 115JAA, and utilise the credit as and when normal tax subsequently exceeds MAT. The scenario memo is refreshed each assessment year against the projected R&D-spend, profit and MAT trajectory. The Section 115(2AB) R&D weighted deduction calculator supports the DSIR-approval-linked deduction quantification that feeds this comparison.

Common reconciliation breakages

Five breakages recur across R&D-heavy Indian pharma companies running the annual Section 115JB MAT computation against a PLI-grant-inclusive book-profit base, and each maps to a specific control failure that a Form 29B rework or a Form 3CB-3CD tax audit qualification will surface.

• PLI grant mis-classified as capital reserve. Some companies attempt to book the PLI grant to a capital reserve on the balance sheet, on the theory that the grant is a capex incentive. The PLI Pharmaceuticals grant is tied to incremental commercial sales — it compensates the entity for incremental commercial activity, not for capital investment. Under Ind AS 20 it is a grant related to income; it belongs in the statement of profit and loss for the period, not in a capital reserve. Mis-classification understates book profit for MAT purposes and produces a Form 29B qualification at the CA MAT report certification.

• Explanation 1 add-back schedule incomplete. The Section 115JB Explanation 1 add-back schedule includes income tax paid, transfer to reserves, provisions for unascertained liabilities, depreciation as per the P&L, deferred tax, and specified other items. Companies that assemble the schedule from prior-year working papers without refreshing against the current-year P&L composition miss items — most commonly the deferred tax charge, revaluation reserve movements, and provision for doubtful debts (an unascertained liability). Missed add-backs understate MAT and expose the company to interest and penalty on assessment.

• Section 115BAA scenario evaluated as a one-way switch. Section 115BAA is irrevocable — once elected, the company cannot revert to the normal regime. Companies that treat the election as a routine year-on-year tax-optimisation choice, without modelling the multi-year impact of surrendering Section 35(2AB) and forfeiting accumulated MAT credit, elect prematurely and lock in a higher effective tax rate for the entire remaining life of the entity. Reconciliation discipline: the Section 115BAA scenario memo must project ten years forward at plausible growth, R&D-intensity and MAT-recoverability assumptions, and must be signed off at board or tax-committee level before election.

• MAT credit deferred tax asset over-recognition. Under Ind AS 12 the DTA for MAT credit is recognised only to the extent it is probable sufficient future taxable profit at the normal-regime rate will be available within the 15-year carry-forward window. R&D-heavy pharma companies that project aggressive R&D-spend forever will structurally never exceed MAT under normal regime — meaning the MAT credit is not recoverable and the DTA should be written down. Companies that carry the full DTA without a defensible recoverability model face an audit qualification and a Section 32AB or Ind AS 12 restatement.

• Human errors in the manual tax-provisioning workflow. The Section 115JB adjusted book-profit computation is typically maintained in an Excel workbook that pulls figures from multiple source ledgers — reserves movement, deferred tax working papers, provision registers, MAT credit register. Manual data-entry errors, formula-drag mistakes, and stale template versions produce quantifiable tax-provision errors that the year-end audit surfaces late. The human errors detection envelope framework maps the specific human-lapse patterns that a reconciliation platform designs against — bounce-pair reversals, transposition errors, formula-drag beyond the intended range — so the tax-provisioning workbook produces a defensible audit trail from the P&L to the MAT computation to the Form 29B report.

How a reconciliation platform handles this

A purpose-built pharma tax-provisioning module ingests the audited Ind AS profit-and-loss composition, the reserves movement schedule, the deferred tax working papers, the DoP PLI disbursement approval feed, and the prior-year MAT credit register — and produces an integrated three-register year-end tax pack: the PLI grant register keyed to the Ind AS 20 recognition entry in the P&L, the Section 115JB adjusted book-profit workbook with Explanation 1 add-backs and reductions line-by-line, and the Section 115JAA MAT credit register with the 15-year carry-forward clock and the Ind AS 12 DTA roll-forward. The parallel Section 115BAA scenario model runs off the same base data with the surrendered-deduction line items switched on and the concessional rate and cess applied — producing a side-by-side comparison that supports the year-on-year tax-strategy decision. Match rate improvement of 51 to 88 percent on the underlying invoice-to-ledger reconciliation feeding the P&L base — combined with an ISO 27001:2022 posture and DPDP Act 2023 aligned data handling — is what makes the platform an infrastructure investment for a Tier-2 pharma formulator running a PLI-recipient tax profile against the R&D-heavy MAT-binding regime. The Pharma reconciliation software India money page and the reconciliation software India authority page carry the commercial detail.

Cross-cluster bridges and where to read next

The Section 115JB MAT interaction documented in this article sits alongside three Wave D pharma tax companions. The Section 115BAA vs PLI pharma concessional-rate election walkthrough covers the multi-year decision framework for the irrevocable Section 115BAA election in more depth, including the interaction with Section 80JJAA new-employment deduction and Section 80M dividend-received deduction that Section 115BAA does not surrender. The PLI Pharma Categories 1, 2 and 3 differential treatment reference walks the sub-category eligibility taxonomy that feeds the grant computation. The Section 35(2AB) weighted deduction pharma R&D reconciliation guide walks the DSIR-approved R&D deduction mechanic that Section 115BAA surrenders — the single most consequential surrendered item for an R&D-heavy pharma company evaluating the concessional-rate switch.

The methodology framework for building the year-end tax-provisioning workbook — separating the Ind AS 20 grant register from the Section 115JB adjustment schedule from the Section 115JAA credit register — sits in Terra Insight’s own reconciliation failure mode analysis pillar and the reconciliation playbook for monthly close operations pillar. The PLI Pharma eligibility tracker supports the underlying grant quantification that flows into the P&L. The commercial pillar for the pharma sub-cluster is Pharma reconciliation software India; the broader authority page for the platform is reconciliation software India.

The five FAQs below address the operational questions Indian pharma tax leads and CFOs ask most often when reconciling PLI Category 1 grant income to the Section 115JB Minimum Alternate Tax computation and the Section 115BAA irrevocable-election evaluation.

Terra Insight Editorial Team Reconciliation Infrastructure

Content authored by practitioners with experience at Amazon India, Intuit QuickBooks, and the Tata Group. Meet the team →

Published 17 July 2026

Domain expertise

TDS Reconciliation GST Input Credit Platform Settlements NACH Batch Matching Bank Reconciliation Form 26AS Matching ERP Integrations Enterprise Finance Ops

Reviewed by

NK

Navin Krishnan

Managing Director & Founder — Terra Insight

Ex Amazon India · Intuit QuickBooks · Tata nexarc

ISO 27001:2022 Patent Pending Incorporated 2024